Biocon targets No.1 global insulin supplier in 5 years

Why Biocon is making insulin its next global push

Biocon Ltd. says it is aiming to become the world’s top supplier of insulin within the next five years, as large pharmaceutical companies increasingly shift attention to newer diabetes therapies such as GLP-1 drugs. The goal was outlined by co-founder and Executive Chairperson Kiran Mazumdar-Shaw in multiple media interactions, including an interview with Bloomberg Television. She said Biocon sees a gap opening up in the insulin category as competitors prioritise other medicines. Biocon believes its manufacturing scale and investments in capacity expansion can help it capture rising global demand for the drug. The company currently supplies insulin to major markets and is looking to widen its footprint further. The target is ambitious, but Biocon argues the industry’s changing priorities are creating room for a focused insulin player.

What Kiran Mazumdar-Shaw said about the five-year goal

Mazumdar-Shaw said Biocon could become the number one insulin company globally within five years. She described the company as one of the few global players with the scale to address that opportunity, pointing to investment in ramping up production capacity. She also said Biocon is positioning itself to be “the” insulin company of the world as larger rivals move towards GLP-1 therapies. In a separate interaction, she said FY26 would be an “acceleration year,” with a “significant windfall” expected from the insulin business. The consistent message across interviews was that Biocon intends to capitalise on a supply and focus shift in global diabetes treatment markets. She also highlighted a manufacturing advantage in delivery formats, stating Biocon is the only company to make insulin in pens and cartridges.

Biocon’s current standing in the insulin market

Biocon is already a large global supplier by volume. The company has emerged as the third-largest supplier by biologic volume of both rh-insulin and insulin glargine worldwide, according to the details shared in the provided material. It also has a meaningful presence in the US market, where it said one in five insulin-dependent patients uses Biocon’s insulin. Beyond the US, the company stated it has approvals across 80 countries and intends to expand in those approved markets. Biocon has also identified 20 emerging markets as growth markets. Taken together, these points indicate that Biocon is building on an existing base rather than entering insulin as a new category.

Capacity expansion: Malaysia facility and the FY27 timeline

A key part of the plan is expanding manufacturing capacity. According to a February 2026 update from Axis Securities, Biocon’s insulin business will double drug product capacity at its Malaysia facility by FY27. The same update said drug substance expansion would follow in FY28-29. Separately, the provided text also notes that Biocon has doubled its insulin manufacturing capacity in Malaysia, reinforcing that Malaysia is central to the scale-up strategy. The company’s leadership has framed this expanded capacity as a way to meet rising demand and fill supply gaps as multinationals step back from the category.

US strategy: interchangeable insulin biosimilars

Biocon has highlighted its position in the US insulin market as a differentiator. It stated it is the only company with interchangeable biosimilar insulin analogues like insulin glargine (Semglee) and insulin aspart (Kirsty) in the US market. Interchangeability is relevant because it can support broader adoption within healthcare systems, depending on regulatory and payer dynamics. The company’s emphasis on interchangeability suggests it is attempting to compete not just on manufacturing scale, but also on product positioning in regulated markets. Biocon has also said it has a significant presence in the US insulin market, and the “one in five” patient usage figure underscores that insulin is already a material part of its US footprint.

Market expansion plans across 80 approved markets

Biocon said it plans to expand its insulin market presence across 80 markets where it has approvals. It has also identified 20 emerging markets as growth markets. The stated aspiration is to tap one in five insulin-dependent patients over the next five years, mirroring its US presence. This approach signals an effort to replicate what it describes as a strong US patient base across other geographies, including India. While the company has not provided a market-by-market rollout schedule in the supplied text, it has clearly linked approvals and capacity expansion with a wider commercial push.

What broker notes say: Axis Securities and Motilal Oswal

The supplied material references two broker perspectives. Axis Securities, in a February 2026 update, described Biocon’s insulin business as “steady” and highlighted the Malaysia drug product capacity doubling by FY27, followed by drug substance expansion in FY28-29. Motilal Oswal added that Biocon is scaling its Insulin Aspart business through hospital networks to drive market penetration. These notes align with Biocon’s stated themes: scaling manufacturing, expanding reach, and using channel strategies such as hospital networks for adoption.

GLP-1 pivot in the industry and Biocon’s parallel build-out

Biocon is framing its insulin opportunity around an industry pivot toward GLP-1 therapies, which it says is drawing focus and manufacturing capacity away from insulin among large rivals. At the same time, the company is also building its own GLP-1 pipeline, according to the supplied text. Mazumdar-Shaw said Biocon’s deep experience in insulin manufacturing and patient familiarity with Biocon devices provide a natural advantage in GLP-1 analogues, suggesting the company sees overlap in manufacturing know-how and device-based usage. The company’s messaging indicates it is not treating insulin and GLP-1 as mutually exclusive, but as adjacent growth areas.

Key facts at a glance

Market impact: what this could mean for competition and supply

If large insulin makers allocate more resources to GLP-1 therapies, insulin supply dynamics can shift toward companies willing to keep investing in the category. Biocon is explicitly attempting to position itself for that opening by expanding capacity and widening market coverage where it already has approvals. For investors tracking the biosimilars and generics space, the company’s focus on both volume leadership and interchangeability in the US market signals an effort to compete on access and scale. The company also flagged its India performance, stating it is the fastest growing insulin company in India with 33% growth, while competitors grew in the range of 5% to 29%, and that it ranks fourth in the insulin market. These points provide context on momentum in a key home market, while the broader strategy remains global.

Analysis: why Biocon’s insulin bet stands out

Biocon’s plan stands out for three reasons evident in the provided information. First, it is tying a clear five-year ambition to a defined industry trend, namely large rivals shifting focus to GLP-1 drugs. Second, it is backing that ambition with a capacity roadmap centred on Malaysia, including a doubling of drug product capacity by FY27, followed by drug substance expansion in FY28-29. Third, it is leaning on regulatory positioning in the US through interchangeable insulin biosimilars, which can strengthen competitiveness in a high-value market. The company is also pairing its insulin focus with a GLP-1 pipeline build, suggesting it wants to participate in the category drawing capital and attention, while using insulin scale to anchor near-term execution.

Conclusion: the milestones to watch next

Biocon has set a clear target to become the world’s top insulin supplier within five years, alongside an ambition to reach 20% share of the global insulin market. Execution will hinge on capacity expansion milestones at its Malaysia facility through FY27 and beyond, and on how quickly it can broaden commercial reach across the 80 markets where it has approvals. The company has also signalled continued work on its GLP-1 pipeline, keeping it exposed to both established and newer diabetes therapy trends. Near-term updates around capacity ramp-up, market launches, and channel expansion such as hospital networks are likely to be the key markers of progress.